Source: Eur Respir J, 57 (4) 2000512; 10.1183/13993003.00512-2020
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Jennifer A. Bartell, Lea M. Sommer, Rasmus L. Marvig, Marianne Skov, Tacjana Pressler, Søren Molin, Helle Krogh Johansen. Omics-based tracking of Pseudomonas aeruginosa persistence in “eradicated” cystic fibrosis patients. Eur Respir J, 57 (4) 2000512; 10.1183/13993003.00512-2020

Member's Comments

No comment yet.

Related content which might interest you: Eradication of Pseudomonas aeruginosa in cystic fibrosis patients Source: Eur Respir J 2006; 27: 653 Year: 2006 Detection of Pseudomonas aeruginosa infection in cystic fibrosis patients by eNose technology Source: International Congress 2018 – Latest developments in cystic fibrosis Year: 2018 Pseudomonas aeruginosa in the home environment of newly infected cystic fibrosis patients Source: Eur Respir J 2008; 31: 822-829 Year: 2008 Epidemiological-molecular study of colonization by pseudomonas aeruginosa in cystic fibrosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 379s Year: 2002 Pseudomonas aeruginosa in patients with cystic fibrosis - a comparison of early eradication and conventional therapy Source: Eur Respir J 2004; 24: Suppl. 48, 385s Year: 2004 Factors associated with infection by Pseudomonas aeruginosa in adult cystic fibrosis Source: Eur Respir J 2005; 26: 651-656 Year: 2005 Antibodies against Pseudomonas aeruginosa in patients with cystic fibrosis – clinical application Source: International Congress 2018 – Cystic fibrosis in paediatric patients: current research Year: 2018 Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre Source: Eur Respir J 2006; 27: 937-943 Year: 2006 Variability of ß-lactamase resistance Pseudomonas aeruginosa genes infecting patients with cystic fibrosis Source: Virtual Congress 2021 – Back to infection basics Year: 2021 Eradication of Pseudomonas aeruginosa in cystic fibrosis Source: Eur Respir J 2006; 27: 438-439 Year: 2006 Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa Source: Eur Respir J 2003; 22: 503-506 Year: 2003 Does sputum induction improve Pseudomonas aeruginosa detection in cystic fibrosis? Source: Eur Respir J 2003; 22: Suppl. 45, 231s Year: 2003 Cystic fibrosis infection with clonal strains of Pseudomonas aeruginosa: current knowledge and future management Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=105 Year: 2006 Epidemiology of Pseudomonas aeruginosa in a cystic fibrosis rehabilitation centre Source: Eur Respir J 2005; 25: 474-481 Year: 2005 Sputum versus bronchoscopy for diagnosis of Pseudomonas aeruginosa biofilms in cystic fibrosis Source: Eur Respir J 2004; 24 : 631-637 Year: 2004 Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis Source: Eur Respir J 2007; 30: 286-292 Year: 2007 Survey of Pseudomonas aeruginosa genotypes in colonised cystic fibrosis patients Source: Eur Respir J 2006 Oct 01;28(4):740-747 Year: 2006 Acquired resistance to macrolides in Pseudomonas aeruginosa from cystic fibrosis patients Source: Eur Respir J, 49 (5) 1601847; 10.1183/13993003.01847-2016 Year: 2017 Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005